MD Anderson Center, The University of Texas
Welcome,         Profile    Billing    Logout  
 5 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cortes, Jorge
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
NCT00930540: DB-67 in Myelodysplastic Syndrome (MDS)

Active, not recruiting
2
25
US
AR-67 (DB-67), DB-67, 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin
M.D. Anderson Cancer Center, Arno Therapeutics
Myelodysplastic Syndrome
12/15
 
ASC4MORE, NCT03578367 / 2018-001594-24: Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Active, not recruiting
2
104
Europe, Canada, US, RoW
Asciminib add-on, ABL001 (asciminib), Imatinib, STI571, Nilotinib, AMN107, Asciminib single agent
Novartis Pharmaceuticals
CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases
11/21
02/25
ALERTCML, NCT05143840: Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

Recruiting
2
8
US
Asciminib, ABL001, Ascimininb + Nilotinib, ABL001 + TASIGNA, Asciminib + Imatinib, ABL001 + Gleevec, Asciminib + Dasatinib, ABL001 + Sprycel
Augusta University, H. Jean Khoury Cure CML Consortium
Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
02/25
02/27
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Recruiting
2
182
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
02/26
02/27
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting
1/2
122
Europe, US, RoW
Vodobatinib (K0706) capsules
Sun Pharma Advanced Research Company Limited
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
08/26
08/26
NCT03038230: MCLA-117 in Acute Myelogenous Leukemia

Checkmark Data from trial for AML at EHA 2020
Jun 2020 - Jun 2020: Data from trial for AML at EHA 2020
Checkmark Initial data in AML
May 2020 - May 2020: Initial data in AML
Checkmark Planned clinical update
More
Active, not recruiting
1
62
Europe, US
MCLA-117 bispecific antibody, bispecific, human bispecific common light chain, bispecific IgG1 targeting CLEC12A and CD3
Merus N.V.
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
07/21
07/21
P-TRP-2447-14, NCT02530034: Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

Active, not recruiting
1
72
US
Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Hu8F4, Laboratory Biomarker Analysis, Pharmacological Study
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Myelofibrosis, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Secondary Acute Myeloid Leukemia
01/26
01/26

Download Options